Q-omics provides the consensus-scored H2BC7 profile across patient tissues and cancer cell-line models. H2BC7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, H2BC7 is differentially expressed in 15, with the highest sampling consensus in LIHC. Additionally, H2BC7 RNA expression shows 20,794 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, LIHC, and LSCC as cancer lineages where H2BC7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2BC7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2BC7 survival associations across molecular data types. H2BC7 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2BC7 RNA expression–survival associations across cancer types. High H2BC7 expression shows unfavorable associations in KIRP, ACC, KIRC and THCA, but favorable associations in STAD and SCLC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for H2BC7 RNA expression.
This table summarizes H2BC7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for H2BC7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2BC7 shows higher tumor expression in LIHC, BLCA, LUAD, KIRC, HNSC and BRCA. The LIHC box plot shows higher H2BC7 RNA expression in tumor versus normal tissue (log2 FC = +1.093, t-test p < 0.001).
This table shows molecular features associated with H2BC7 in patient tissues and cancer cell lines. In patient samples, H2BC7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, H2BC7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
